Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

For Biogen, dapirolizumab pegol is part of a push ... also partnered with UCB – and felzartamab, an anti-CD38 antibody for IgA nephropathy (IgAN) and other diseases, licensed from Human ...

After hours: March 21 at 7:27:47 PM EDT Loading Chart for BIIB ...

11.02. Mustang Bio, Inc.: Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement 117 GlobeNewswire (Europe) WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc ...

After hours: March 21 at 7:27:47 PM EDT ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After hours: 13 March at 7:37:36 pm GMT-4 Loading Chart for BIIB ...

After hours: 20 March at 19:52:57 GMT-4 Loading Chart for BIIB ...